{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:44:05Z","timestamp":1791495845608,"version":"4.3.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:p>Approximately 60% of individuals with a spinal cord injury (SCI) experience neuropathic pain, which often persists despite the use of various pharmacological treatments. Increasingly, the potential analgesic effects of cannabis and cannabinoid products have been studied; however, little research has been conducted among those with SCI-related neuropathic pain. Therefore, the primary objective of the study was to investigate the perceived effects of cannabis and cannabinoid use on neuropathic pain among those who were currently or had previously used these approaches. Additionally, the study aimed to determine if common pain medications are being substituted by cannabis and cannabinoids. Participants (<jats:italic>N<\/jats:italic>\u2009=\u2009342) were recruited from existing opt-in listserv sources within the United States. Of those, 227 met the inclusion criteria and were enrolled in the study. The participants took part in an anonymous online survey regarding past and current use of cannabis and their perceived effects on neuropathic pain, including the use of pain medication. Those in the sample reported average neuropathic pain intensity scores over the past week of 6.8\u2009\u00b1\u20092.1 (0 to 10 scale), reflecting a high moderate to severe level of pain. Additionally, 87.9% noted that cannabis reduced their neuropathic pain intensity by more than 30%, and 92.3% reported that cannabis helped them to better deal with their neuropathic pain symptoms. Most participants (83.3%) also reported substituting their pain medications with cannabis, with the most substituted medication categories being opioids (47.0%), gabapentinoids (42.8%) and over-the-counter pain medications (42.2%). These preliminary results suggest that cannabis and cannabinoids may be effective in reducing neuropathic pain among those with SCI and may help to limit the need for certain pain medications.<\/jats:p>","DOI":"10.3389\/fpain.2023.1297223","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:49:20Z","timestamp":1703134160000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A preliminary study evaluating self-reported effects of cannabis and cannabinoids on neuropathic pain and pain medication use in people with spinal cord injury"],"prefix":"10.3389","volume":"4","author":[{"given":"Kristiina","family":"Kinnunen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda E.","family":"Robayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Cherup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott I.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Widerstr\u00f6m-Noga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1136\/rapm-2020-101960","article-title":"Prevalence of chronic pain after spinal cord injury: a systematic review and meta-analysis","volume":"46","author":"Hunt","year":"2021","journal-title":"Reg Anesth Pain Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0003-9993(99)90203-4","article-title":"Perceived difficulty in dealing with consequences of spinal cord injury","volume":"80","author":"Widerstr\u00f6m-Noga","year":"1999","journal-title":"Arch Phys Med Rehabil"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1053\/apmr.2002.35651","article-title":"Classification of chronic pain associated with spinal cord injuries","volume":"83","author":"Cardenas","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"key":"B4","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/sc.2011.156","article-title":"International spinal cord injury pain classification: part I. Background and description. March 6\u20137, 2009","volume":"50","author":"Bryce","year":"2012","journal-title":"Spinal Cord"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1097\/j.pain.0000000000001051","article-title":"Cannabis constituent synergy in a mouse neuropathic pain model","volume":"158","author":"Casey","year":"2017","journal-title":"Pain"},{"key":"B6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.pain.2008.10.007","article-title":"Neuropathic pain and primary somatosensory cortex reorganization following spinal cord injury","volume":"141","author":"Wrigley","year":"2009","journal-title":"Pain"},{"key":"B7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41393-021-00744-z","article-title":"The CanPain SCI clinical practice guidelines for rehabilitation management of neuropathic pain after spinal cord injury: 2021 update","volume":"60","author":"Loh","year":"2022","journal-title":"Spinal Cord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1093\/pm\/pnaa058","article-title":"Barriers and facilitators to optimal neuropathic pain management: SCI consumer, significant other, and health care provider perspectives","volume":"21","author":"Widerstrom-Noga","year":"2020","journal-title":"Pain Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2165\/00023210-200822060-00002","article-title":"Pharmacological management of neuropathic pain following spinal cord injury","volume":"22","author":"Baastrup","year":"2008","journal-title":"CNS Drugs"},{"key":"B10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41394-019-0227-3","article-title":"Using cannabis for pain management after spinal cord injury: a qualitative study","volume":"5","author":"Bourke","year":"2019","journal-title":"Spinal Cord Ser Cases"},{"key":"B11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40263-021-00879-w","article-title":"Cannabis-based medicines and medical cannabis for chronic neuropathic pain","volume":"36","author":"Petzke","year":"2022","journal-title":"CNS Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.785176","article-title":"Cannabinoid therapeutics in chronic neuropathic pain: from animal research to human treatment","volume":"12","author":"Campos","year":"2021","journal-title":"Front Physiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.nurt.2009.08.002","article-title":"Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside","volume":"6","author":"Rahn","year":"2009","journal-title":"Neurotherapeutics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41386-019-0585-3","article-title":"Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain","volume":"45","author":"Abraham","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br J Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0301-0082(00)00031-9","article-title":"Cannabinoid receptors and pain","volume":"63","author":"Pertwee","year":"2001","journal-title":"Prog Neurobiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.bjp.0707531","article-title":"Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain","volume":"153","author":"Guindon","year":"2008","journal-title":"Br J Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.bjp.0707440","article-title":"Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate","volume":"152","author":"Rea","year":"2007","journal-title":"Br J Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/bs.apha.2017.05.003","article-title":"Cannabinoids and pain: sites and mechanisms of action","volume":"80","author":"Starowicz","year":"2017","journal-title":"Adv Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.drugpo.2013.08.010","article-title":"Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use","volume":"24","author":"Walsh","year":"2013","journal-title":"Int J Drug Policy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.drugalcdep.2016.12.030","article-title":"The impact of cannabis and cannabinoids for medical conditions on health-related quality of life: a systematic review and meta-analysis","volume":"174","author":"Goldenberg","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"B22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2340\/16501977-2105","article-title":"Cannabis use in persons with traumatic spinal cord injury in Denmark","volume":"49","author":"Andresen","year":"2017","journal-title":"J Rehabil Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1310\/sci2201-3","article-title":"Characteristics of individuals with spinal cord injury who use cannabis for therapeutic purposes","volume":"22","author":"Drossel","year":"2016","journal-title":"Top Spinal Cord Inj Rehabil"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/j.apmr.2018.02.003","article-title":"Cannabis use in individuals with spinal cord injury or moderate to severe traumatic brain injury in Colorado","volume":"99","author":"Hawley","year":"2018","journal-title":"Arch Phys Med Rehabil"},{"key":"B25","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/10790268.2022.2038049","article-title":"Cannabis health survey on usage in women with spinal cord injury and knowledge among physicians: a cross-sectional study","volume":"46","author":"Lee","year":"2023","journal-title":"J Spinal Cord Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41394-018-0096-1","article-title":"Cannabis shenanigans: advocating for the restoration of an effective treatment of pain following spinal cord injury","volume":"4","author":"Graves","year":"2018","journal-title":"Spinal Cord Ser Cases"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.outlook.2017.08.012","article-title":"The use of cannabis in response to the opioid crisis: a review of the literature","volume":"66","author":"Vyas","year":"2018","journal-title":"Nurs Outlook"},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41394-019-0208-6","article-title":"Utilization of medicinal cannabis for pain by individuals with spinal cord injury","volume":"5","author":"Stillman","year":"2019","journal-title":"Spinal Cord Ser Cases"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.3390\/ph16081079","article-title":"Cannabis-based medicine for neuropathic pain and spasticity\u2014a multicenter, randomized, double-blinded, placebo-controlled trial","volume":"16","author":"Hansen","year":"2023","journal-title":"Pharmaceuticals"},{"key":"B31","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/ajad.12598","article-title":"Nonmedical versus medical marijuana use among three age groups of adults: associations with mental and physical health status","volume":"26","author":"Choi","year":"2017","journal-title":"Am J Addict"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e0178194","DOI":"10.1371\/journal.pone.0178194","article-title":"Measuring cannabis consumption: psychometric properties of the daily sessions, frequency, age of onset, and quantity of cannabis use inventory (DFAQ-CU)","volume":"12","author":"Cuttler","year":"2017","journal-title":"PLoS One"},{"key":"B33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/00952990.2013.821477","article-title":"Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users","volume":"40","author":"Bonn-Miller","year":"2014","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pain.2010.07.031","article-title":"NeuPSIG guidelines on neuropathic pain assessment","volume":"152","author":"Haanp\u00e4\u00e4","year":"2011","journal-title":"Pain"},{"key":"B35","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/sj.sc.3101777","article-title":"Chronic pain in individuals with spinal cord injury: a survey and longitudinal study","volume":"43","author":"Jensen","year":"2005","journal-title":"Spinal Cord"},{"key":"B36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jpain.2005.09.011","article-title":"Pain interference in persons with spinal cord injury: classification of mild, moderate, and severe pain","volume":"7","author":"Hanley","year":"2006","journal-title":"J Pain"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1053\/apmr.2001.26068","article-title":"Chronic pain after spinal injury: interference with sleep and daily activities","volume":"82","author":"Widerstr\u00f6m-Noga","year":"2001","journal-title":"Arch Phys Med Rehabil"},{"key":"B38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41393-017-0014-6","article-title":"Increased psychological distress among individuals with spinal cord injury is associated with central neuropathic pain rather than the injury characteristics","volume":"56","author":"Gruener","year":"2018","journal-title":"Spinal Cord"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/sc.2017.70","article-title":"Neuropathic pain and spasticity: intricate consequences of spinal cord injury","volume":"55","author":"Finnerup","year":"2017","journal-title":"Spinal Cord"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/AJP.0000000000000364","article-title":"The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study","volume":"32","author":"Haroutounian","year":"2016","journal-title":"Clin J Pain"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/cpt.1381","article-title":"Positive and negative effects of cannabis and cannabinoids on health","volume":"105","author":"Cohen","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.apmr.2017.12.004","article-title":"Dose and duration of opioid use in propensity score matched, privately insured opioid users with and without spinal cord injury","volume":"99","author":"Hand","year":"2018","journal-title":"Arch Phys Med Rehabil"},{"key":"B43","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/add.13670","article-title":"Demographic trends among older cannabis users in the United States, 2006\u201313","volume":"112","author":"Han","year":"2017","journal-title":"Addict Abingdon Engl"},{"key":"B44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.drugalcdep.2016.06.002","article-title":"Trends in cannabis use disorders among racial\/ethnic population groups in the United States","volume":"165","author":"Wu","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"B45","first-page":"53","article-title":"Medical cannabis use among adults in the southeastern United States","volume":"2","author":"Salazar","year":"2019","journal-title":"Cannabis Res Soc Marijuana"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2023.1297223\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:49:24Z","timestamp":1703134164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2023.1297223\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":45,"alternative-id":["10.3389\/fpain.2023.1297223"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2023.1297223","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"article-number":"1297223"}}